|
| Status |
Public on Dec 19, 2020 |
| Title |
Gene expression profiling of erlotinib-resistant PC9 cells. |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The non-small cell lung carcinoma (NSCLC) PC9 cell line is an established preclinical model for tyrosine kinase inhibitors. To better understand gene expression changes in cells that survived the inhibitor treatment, we treated the EGFR-mutant PC9 cells with erlotinib, isolated RNA, and performed RNA-seq analysis. We were able to identify genes that are differentially expressed in erlotinib-treated cells compared to untreated. The results of this study will be integrated with single cell RNA-seq to address the utility of bulk RNA versus single cell RNA strategies in identifying biomarkers of drug resistance.
|
| |
|
| Overall design |
examining changes associated with drug resistance using RNA-seq
|
| |
|
| Contributor(s) |
Benevolenskaya EV, BIslam A, Go C |
| Citation(s) |
33712615 |
| NIH grant(s) |
| Grant ID |
Grant title |
Affiliation |
Name |
| R01 CA211095 |
Role of KDM5A in pRB-mediated differentiation |
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
Elizaveta V Benevolenskaya |
|
| |
| Submission date |
Apr 10, 2020 |
| Last update date |
Mar 22, 2021 |
| Contact name |
Elizaveta V Benevolenskaya |
| E-mail(s) |
[email protected]
|
| Phone |
312-413-8947
|
| Organization name |
University of Illinois at Chicago
|
| Department |
Biochemistry and Molecular Genetics
|
| Street address |
900 S. Ashland Ave.
|
| City |
Chicago |
| State/province |
IL |
| ZIP/Postal code |
60607 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL11154 |
Illumina HiSeq 2000 (Homo sapiens) |
|
| Samples (4)
|
|
| Relations |
| BioProject |
PRJNA624326 |
| SRA |
SRP255970 |
Less...
More...